- Trial phase
- Phase 3
- Time to market
- Regulatory submissions for IPF have not yet been filed. If BMS submits an NDA in 2027, a potential FDA decision could come in 2028 under standard review, or sooner if Breakthrough Therapy Designation for PPF expedites the IPF review. The ALOFT-PPF readout in early 2027 will also inform the regulatory path.
- Why 4/10
- The next hard catalyst is the Phase 3 ALOFT-PPF topline readout in progressive pulmonary fibrosis, expected in early 2027 (no specific date yet). Admilparant is a meaningful pipeline asset but represents only a ~5% DCF swing factor for diversified large-cap BMY, limiting the stock-level impact of any single catalyst.
Watch for the ALOFT-PPF topline readout in early 2027, which will determine whether admilparant can expand into the broader progressive pulmonary fibrosis market. A positive PPF result would strengthen the drug's commercial case ahead of planned regulatory submissions for IPF. Also monitor for any announced NDA submission date, which would set a PDUFA calendar.
Price Chart
Executive Summary
Admilparant (BMS-986278) is Bristol Myers Squibb's investigational first-in-class oral LPA1 antagonist for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). On October 12, 2026, BMS announced that the pivotal Phase 3 ALOFT-IPF trial met its primary endpoint at the 60 mg twice-daily dose, showing a statistically significant improvement in lung function (FVC) versus placebo at 52 weeks, though the 120 mg dose missed statistical significance. The drug showed a favorable safety profile. BMS plans to engage with health authorities for regulatory submissions, though no NDA has been filed yet and no PDUFA date exists. A second Phase 3 trial (ALOFT-PPF) in progressive pulmonary fibrosis is fully enrolled with topline results expected in early 2027. For diversified large-cap BMY, admilparant represents a modest value driver (Goldman Sachs estimates ~5% DCF impact), with William Blair forecasting $1.3B in IPF sales by 2032.
How It Works
Admilparant is an experimental pill that blocks a protein called LPA1, which is involved in the scarring process in the lungs. By blocking this target, the drug aims to slow the progression of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), two serious lung-scarring diseases that make it progressively harder to breathe.
Trial Status
The Phase 3 ALOFT-IPF trial (IPF) has completed with positive topline results at 60 mg announced October 12, 2026. The Phase 3 ALOFT-PPF trial (progressive pulmonary fibrosis) is fully enrolled with topline results expected in early 2027. A long-term extension study is also ongoing.
The Two-Sided Case
Upcoming Catalysts
- Phase 3 ALOFT-PPF topline results in progressive pulmonary fibrosis (early 2027)
- Regulatory submissions (NDA/MAA) for IPF following engagement with health authorities (timeline not specified)
- Presentation of full ALOFT-IPF data at a future medical meeting
Source Filing
The SecBot filing or press-release report that triggered this drug report:
BRISTOL MYERS SQUIBB CO 8-K BMY ·Originating report